AR032279A1 - Metodo para inhibir una o mas actividades de quinasa proteinica, compuesto de 2 - pirazolin-5-ona inhibidor de quinasa proteinica y composicion farmaceutica que lo comprende - Google Patents

Metodo para inhibir una o mas actividades de quinasa proteinica, compuesto de 2 - pirazolin-5-ona inhibidor de quinasa proteinica y composicion farmaceutica que lo comprende

Info

Publication number: AR032279A1
Authority: AR; Argentina
Prior art keywords: group; proteinic; cycloalkyl; inhibiting; pharmaceutical composition
Prior art date: 1999-07-30

Application number

ARP000103955A

Other languages

English (en)

Spanish (es)

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-30

Filing date

2000-07-31

Publication date

2003-11-05

2000-07-31 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2003-11-05 Publication of AR032279A1 publication Critical patent/AR032279A1/es

Links

102000001253 Protein Kinase Human genes 0.000 title abstract 2
230000000694 effects Effects 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
108060006633 protein kinase Proteins 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 2
-1 2-pyrazolin-5-one compound Chemical class 0.000 abstract 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
125000006529 (C3-C6) alkyl group Chemical group 0.000 abstract 1
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 abstract 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical compound C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 abstract 1
KQBVVLOYXDVATK-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indole Chemical compound C1CCCC2=C1C=CN2 KQBVVLOYXDVATK-UHFFFAOYSA-N 0.000 abstract 1
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 abstract 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
125000001931 aliphatic group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Oncology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ARP000103955A 1999-07-30 2000-07-31 Metodo para inhibir una o mas actividades de quinasa proteinica, compuesto de 2 - pirazolin-5-ona inhibidor de quinasa proteinica y composicion farmaceutica que lo comprende AR032279A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US14656399P	1999-07-30	1999-07-30

Publications (1)

Publication Number	Publication Date
AR032279A1 true AR032279A1 (es)	2003-11-05

Family

ID=22517965

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP000103955A AR032279A1 (es)	1999-07-30	2000-07-31	Metodo para inhibir una o mas actividades de quinasa proteinica, compuesto de 2 - pirazolin-5-ona inhibidor de quinasa proteinica y composicion farmaceutica que lo comprende

Country Status (21)

Country	Link
EP (1)	EP1218373A2 (cs)
JP (1)	JP2003506368A (cs)
KR (1)	KR20020091829A (cs)
CN (1)	CN1193026C (cs)
AR (1)	AR032279A1 (cs)
AU (1)	AU6388900A (cs)
BG (1)	BG106392A (cs)
BR (1)	BR0012896A (cs)
CA (1)	CA2380644A1 (cs)
CZ (1)	CZ2002302A3 (cs)
HK (1)	HK1049154A1 (cs)
HU (1)	HUP0400540A3 (cs)
IL (1)	IL147757A0 (cs)
MX (1)	MXPA02001088A (cs)
NO (1)	NO20020487L (cs)
NZ (1)	NZ516850A (cs)
PL (1)	PL354144A1 (cs)
SK (1)	SK1512002A3 (cs)
TR (1)	TR200200928T2 (cs)
WO (1)	WO2001009121A2 (cs)
ZA (1)	ZA200200477B (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6455525B1 (en)	1999-11-04	2002-09-24	Cephalon, Inc.	Heterocyclic substituted pyrazolones
WO2003011287A1 (en) *	2001-08-03	2003-02-13	Vertex Pharmaceuticals Incorporated	Pyrazolon derivatives as inhibitors of gsk-3
AU2003249865A1 (en) *	2003-06-24	2005-01-21	Actelion Pharmaceuticals Ltd	Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
JPWO2005012255A1 (ja) *	2003-08-01	2006-09-14	三菱ウェルファーマ株式会社	炎症性関節疾患の治療剤
CA2541603A1 (en) *	2003-10-14	2005-04-21	Kringle Pharma Inc.	Agent for improving mental disorders
CN1925855B (zh)	2003-12-19	2010-06-16	普莱希科公司	开发Ret调节剂的化合物和方法
GB0329617D0 (en) *	2003-12-23	2004-01-28	Astex Technology Ltd	Pharmaceutical compounds
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
WO2006124874A2 (en) *	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibitors of b-raf kinase
JPWO2006129587A1 (ja) *	2005-05-30	2009-01-08	株式会社ジーンケア研究所	ピラゾロン誘導体を含有する医薬組成物
EP1905762A1 (en) *	2005-05-30	2008-04-02	Genecare Research Institute Co., Ltd	Pyrazolone derivative
US7371862B2 (en)	2005-11-11	2008-05-13	Pfizer Italia S.R.L.	Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE102005057924A1 (de) *	2005-12-05	2007-06-06	Merck Patent Gmbh	Pyridazinonderivate
CA2632626C (en)	2005-12-09	2011-10-11	F. Hoffmann-La Roche Ag	Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
KR101057239B1 (ko)	2006-10-10	2011-08-16	에프. 호프만-라 로슈 아게	뉴클레오사이드 리보푸라노실 피리미딘의 제조
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
WO2009012283A1 (en)	2007-07-17	2009-01-22	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
KR100987557B1 (ko) *	2008-03-18	2010-10-12	이화여자대학교 산학협력단	혈관 재협착 치료 또는 예방용 조성물
US9145424B2 (en)	2008-11-20	2015-09-29	Northwestern University	Treatment of amyotrophic lateral sclerosis
ES2668556T3 (es)	2008-11-20	2018-05-18	Northwestern University	Derivados de pirazolona útiles en el tratamiento de esclerosis lateral amiotrófica
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
MY172424A (en)	2009-04-03	2019-11-25	Hoffmann La Roche	Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
CN106220623A (zh)	2009-11-06	2016-12-14	普莱希科公司	用于激酶调节的化合物和方法及其适应症
SG184324A1 (en)	2010-03-31	2012-11-29	Gilead Pharmasset Llc	Nucleoside phosphoramidates
CA2818853A1 (en)	2010-11-30	2012-06-07	Gilead Pharmasset Llc	2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US9624213B2 (en)	2011-02-07	2017-04-18	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es)	2011-02-21	2013-09-18	Plexxikon Inc	Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
EP2876109A4 (en) *	2012-07-23	2016-03-16	Yuhan Corp	CONDENSED RING CONNECTION WITH FURAN OR SALT AND PHARMACEUTICAL COMPOSITIONS THEREWITH
NZ722345A (en)	2014-02-14	2018-02-23	Inception 2 Inc	Pyrazolone compounds and uses thereof
CN105037269B (zh) *	2015-07-10	2018-01-19	中国人民解放军第二军医大学	取代吡唑酮类分泌型天冬氨酸蛋白酶抑制剂及其制备方法
TWI796353B (zh)	2017-08-15	2023-03-21	美商阿吉歐斯製藥公司	丙酮酸激酶調節劑及其用途
KR102625224B1 (ko) *	2018-10-31	2024-01-15	주식회사 큐로젠	피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
CN111793032B (zh) *	2019-04-08	2021-11-19	四川省中医药科学院	一类吡唑啉酮类化合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4369310A (en) *	1979-11-19	1983-01-18	Ciba-Geigy Ltd.	Bleachable dyes
JPH078851B2 (ja) *	1985-07-29	1995-02-01	鐘淵化学工業株式会社	３−フエニルチオメチルスチレン誘導体
JPS6229570A (ja) *	1985-07-29	1987-02-07	Kanegafuchi Chem Ind Co Ltd	３，５−ジイソプロピルベンジリデン複素環式化合物
JP2678822B2 (ja) *	1990-06-04	1997-11-19	富士写真フイルム株式会社	ハロゲン化銀写真感光材料

2000
- 2000-07-28 CA CA002380644A patent/CA2380644A1/en not_active Abandoned
- 2000-07-28 HU HU0400540A patent/HUP0400540A3/hu unknown
- 2000-07-28 CN CNB008136823A patent/CN1193026C/zh not_active Expired - Fee Related
- 2000-07-28 TR TR2002/00928T patent/TR200200928T2/xx unknown
- 2000-07-28 BR BR0012896-1A patent/BR0012896A/pt not_active IP Right Cessation
- 2000-07-28 SK SK151-2002A patent/SK1512002A3/sk unknown
- 2000-07-28 WO PCT/US2000/020628 patent/WO2001009121A2/en not_active Ceased
- 2000-07-28 EP EP00950852A patent/EP1218373A2/en not_active Withdrawn
- 2000-07-28 MX MXPA02001088A patent/MXPA02001088A/es unknown
- 2000-07-28 AU AU63889/00A patent/AU6388900A/en not_active Abandoned
- 2000-07-28 PL PL00354144A patent/PL354144A1/xx not_active Application Discontinuation
- 2000-07-28 KR KR1020027001343A patent/KR20020091829A/ko not_active Withdrawn
- 2000-07-28 NZ NZ516850A patent/NZ516850A/en unknown
- 2000-07-28 HK HK02109301.3A patent/HK1049154A1/zh unknown
- 2000-07-28 CZ CZ2002302A patent/CZ2002302A3/cs unknown
- 2000-07-28 IL IL14775700A patent/IL147757A0/xx unknown
- 2000-07-28 JP JP2001514324A patent/JP2003506368A/ja not_active Withdrawn
- 2000-07-31 AR ARP000103955A patent/AR032279A1/es unknown
2002
- 2002-01-18 ZA ZA200200477A patent/ZA200200477B/xx unknown
- 2002-01-30 NO NO20020487A patent/NO20020487L/no not_active Application Discontinuation
- 2002-02-06 BG BG106392A patent/BG106392A/bg unknown

Also Published As

Publication number	Publication date
CN1193026C (zh)	2005-03-16
PL354144A1 (en)	2003-12-29
CA2380644A1 (en)	2001-02-08
HK1049154A1 (zh)	2003-05-02
AU6388900A (en)	2001-02-19
HUP0400540A2 (hu)	2004-06-28
NO20020487L (no)	2002-03-12
SK1512002A3 (en)	2002-11-06
NZ516850A (en)	2004-09-24
ZA200200477B (en)	2003-06-25
BR0012896A (pt)	2002-06-18
BG106392A (bg)	2002-12-29
NO20020487D0 (no)	2002-01-30
MXPA02001088A (es)	2003-09-22
IL147757A0 (en)	2002-08-14
WO2001009121A2 (en)	2001-02-08
WO2001009121A3 (en)	2002-05-02
EP1218373A2 (en)	2002-07-03
JP2003506368A (ja)	2003-02-18
CN1377346A (zh)	2002-10-30
CZ2002302A3 (cs)	2002-06-12
HUP0400540A3 (en)	2004-09-28
TR200200928T2 (tr)	2002-09-23
KR20020091829A (ko)	2002-12-06

Legal Events

Date	Code	Title	Description
2004-02-20	FB	Suspension of granting procedure

Publication	Publication Date	Title
AR032279A1 (es)	2003-11-05	Metodo para inhibir una o mas actividades de quinasa proteinica, compuesto de 2 - pirazolin-5-ona inhibidor de quinasa proteinica y composicion farmaceutica que lo comprende
UY24434A1 (es)	1997-06-06	Nuevos imidazoles sustituidos con cicloalquilo
JP5559701B2 (ja)	2014-07-23	イミダゾリウム及びイミダゾリニウム化合物で線維症及び癌を治療する方法
TWI226329B (en)	2005-01-11	Compounds of the formula I for the treatment of ischemia, and pharmaceutical composition comprising the same
RU2337909C2 (ru)	2008-11-10	Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
DE68907921D1 (de)	1993-09-09	Substituierte pyrrol-, pyrazol- und triazol-angiotensin ii-antagonisten.
ATE266028T1 (de)	2004-05-15	1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation
NO986087L (no)	1999-02-26	Oralt preparat omfattende en antifungal triazolforbindelse
AR041262A1 (es)	2005-05-11	Metodos para tratar los trastornos de ojo seco
NZ597647A (en)	2013-08-30	Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CA2509982A1 (en)	2004-06-10	N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
AU2005237788A1 (en)	2005-11-10	Indole and azaindole derivatives with antitumor action
EA200000488A1 (ru)	2000-10-30	Замена катехина на биоизостеру индазола в терапевтически активных соединениях
JP2002544199A (ja)	2002-12-24	ヘテロ環置換されたベンズイミダゾール、その製造方法およびその使用
NO177006B (no)	1995-03-27	Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-R2-R4-substituert-3-R3-CO-1-[(C-tilknyttet-N-hetryl)-(Alk)nÅ-1H-indoler, samt mellomprodukt for bruk i denne
YU173791A (sh)	1994-01-20	Indol i benzimidazol-supstituisani imidazol i benzimidazol derivati
PE20081850A1 (es)	2009-02-05	Derivados ciclizados como inhibidores de la eg-5
CN101272782A (zh)	2008-09-24	作为生长激素促分泌受体的ghrelin类似物配体的新颖的三唑衍生物
TR200002097A2 (tr)	2001-02-21	Triazol ve imidazol türevleri
RU2403250C2 (ru)	2010-11-10	Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5
JO2274B1 (en)	2005-04-07	Derivatives of 1-renesulfinyl-2-aryl-pyrrolidine and piperidine
KR20010085305A (ko)	2001-09-07	이치환된 말레이미드 화합물 및 그의 의약 용도
ATE246684T1 (de)	2003-08-15	Substituierte 1,4-dihydroindeno(1,2-c)pyrazole als inhibitoren von tyrosinkinase
JP2006516604A (ja)	2006-07-06	５ｈｔ７アンタゴニストおよび逆アゴニスト
ES8407488A1 (es)	1984-10-01	Un procedimiento para la preparacion de nuevos derivados de triazol.